Blog

Pediatric drug development: From “wild west” to model-informed confidence

Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…

CertaraFebruary 11, 2026

Blog

QSP in inflammatory bowel disease (IBD): From biomarkers to clinical endpoints, with virtual patients

Certara supports IBD drug development with a QSP model that predicts Mayo score and CDAI…

CertaraFebruary 10, 2026

Publication

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…

CertaraFebruary 2, 2026

Conference

Quantitative Systems Pharmacology Conference

CertaraJanuary 26, 2026

Blog

How model-informed drug development (MIDD) strengthens drug asset valuation and answers the questions investors care about most

Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…

CertaraJanuary 26, 2026

Publication

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…

CertaraJanuary 22, 2026

On-Demand Webinar

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…

CertaraJanuary 22, 2026

Blog

Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus

Leveraging adaptive clinical trial designs in oncology can accelerate drug development, while following the FDA…

CertaraJanuary 16, 2026

Webinar

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

CertaraJanuary 14, 2026

On-Demand Webinar

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

Watch this on-demand webinar featuring former regulators as they share global regulatory trends and clinical…

CertaraJanuary 14, 2026

Modeling and Simulation

Pediatric drug development: From “wild west” to model-informed confidence

QSP in inflammatory bowel disease (IBD): From biomarkers to clinical endpoints, with virtual patients

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

Quantitative Systems Pharmacology Conference

How model-informed drug development (MIDD) strengthens drug asset valuation and answers the questions investors care about most

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

Newsletter sign up

Quick links

Solutions

Contact